论文部分内容阅读
良性前列腺增生症(BPH)是老年人常见疾病,随着平均寿命的延长和营养结构的改变,近半个世纪以来发病率有所增长。最新统计表明,我国50岁以上男性前列腺增生发生率为51.2%,50～60岁57.75%,60～70岁67.5%,70～80岁74.26%,80岁以上为76.92%。发生率和世界其它地区基本相同,与年龄明显呈正相关。在前列腺增生的老年人中约有40%发生尿路梗阻,需要药物和手术治疗。药物治疗适用于轻、中度前列腺增生所致下尿路症状(LUTS)的患者,临床最常用的药物有α-肾上腺素能受体阻断剂和5 α-还原酶抑制剂。前者可以
Benign prostatic hyperplasia (BPH) is a common disease in the elderly, with the average life expectancy and nutritional changes in the structure, the incidence of nearly half a century increased. The latest statistics show that the incidence of benign prostatic hyperplasia in men over the age of 50 in China was 51.2%, 57.75% at 50-60 years, 67.5% at 60-70 years, 74.26% at 70-80 years and 76.92% at 80 years of age. The incidence is basically the same as that of the rest of the world, with a clear positive correlation with age. About 40% of the elderly with BPH develop urinary tract obstruction requiring medication and surgery. Drug therapy for mild to moderate benign prostatic hyperplasia caused by lower urinary tract symptoms (LUTS) patients, the most commonly used clinical drugs α-adrenergic receptor blockers and 5 α-reductase inhibitors. The former can